The other really interesting new information for me was the expansion of the variants for BTM and MTX based on physician requests (market feedback)
1. Different thickness options for different parts of the body was a great opportunity to broaden the market for both BTM and MTX.
2. The larger 40cm format for large surface area wounds.
3. The roll package option for ease if continuous application around limbs and torso for better coverage with less joins.
4. The addition of antibacterial coating to the Novosorb matrix. This means that not only is it non-biologic and takes away the "food" for the bugs, but it also can actively treat residual infection as a default. This will improve the tolerance to dirty wounds from good to great and provide a value big add at low cost.
Ann: FY24 Results Presentation, page-38
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.03 |
Change
0.010(0.50%) |
Mkt cap ! $1.405B | |||
| Open | High | Low | Value | Volume |
| $2.03 | $2.06 | $2.01 | $1.230M | 606.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 17179 | $2.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.03 | 21495 | 32 |
View Market Depth
| Last trade - 15.15pm 04/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |